US Pharma MarketingRoche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
The decision comes after tominersen did no better than placebo in a Phase 2 trial with patients in the earliest stages of the disease. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
After more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen.
The decision comes after tominersen did no better than placebo in a Phase 2 ...
Source: Endpoints News